CRISIL Share Price Target 2026, 2027, 2028, 2029, 2030

CRISIL share price today

CRISIL (NSE: CRISIL) is two annuities under one S&P-controlled roof. The first: India’s premier credit-rating franchise — the name treasurers ask for first in a regulated oligopoly where demand is written into law. The second, larger by revenue: global research and analytics — risk models, benchmarking and research delivered to international banks and buy-side firms from Indian cost bases, an offshore annuity the rating multiple tends to obscure.

The blend produces 32.6% ROCE, 29.8% operating margins, and the steadiest earnings stream in its peer group. At 36.2×, our universe tags it wait: two quality annuities, both fully recognised by the price on most days.

Ratings prestige, analytics scale

In ratings, CRISIL’s brand premium wins the marquee mandates and prices above the field — reputation is the product, and S&P parentage compounds it. In analytics, the Global Research & Risk Solutions arm rides two structural flows: financial-institution cost pressure (offshoring model risk and research) and regulatory complexity (every new capital rule is billable work). Neither business needs capital; both throw off cash.

Watch-items: bond-issuance cycles for the ratings arm, global banking cost cycles for analytics (bank belt-tightening cuts research budgets too), S&P’s related-party pricing, and the rupee (analytics revenue is substantially dollar-linked).

The numbers

From our research universe snapshot (5 Aug 2026):

Metric	Value
Market cap	₹32,025 Cr
P/E (TTM)	36.2
EV/EBITDA	23.7
Operating margin	29.8%
ROE / ROCE	24.5% / 32.6%
Debt to equity	0.10
Sales CAGR (5y)	13.0%
Profit CAGR (5y)	14.4%
Promoter holding	66.6% (S&P Global)
EPS (TTM)	₹120.3

CRISIL share price target 2026 to 2030

EPS base ₹120.3 (TTM). Bear: issuance softens and bank research budgets shrink — 8% growth, multiple at 24×. Base: both annuities compound low-teens — 13% growth at 31×. Bull: bond-market deepening plus analytics wins — 17% growth at 40×.

Year	Bear (24×, +8%)	Base (31×, +13%)	Bull (40×, +17%)
2026	₹3,120	₹4,215	₹5,630
2027	₹3,370	₹4,760	₹6,585
2028	₹3,635	₹5,380	₹7,705
2029	₹3,930	₹6,080	₹9,015
2030	₹4,240	₹6,870	₹10,550

From ₹4,357, the base case is ≈ +58% over four and a half years plus dividends; the bear is −3%. Downside this shallow is what dual annuities buy — the range below simply insists on paying annuity prices for them.

Reasons to own CRISIL (at the right price)

1. The premium seat in a regulated ratings oligopoly — reputation prices above the field.
2. Global analytics is a second annuity most rating-stock analyses undercount.
3. S&P parentage: governance, technology and referral flow.
4. 33% ROCE with negligible capital needs — cash compounds or returns.
5. Dollar-linked analytics revenue hedges the domestic cycle.

The risks: global bank cost-cutting hits analytics first, ratings reputation is one scandal from damage, and a 66.6% parent sets strategy minorities ride along with.

Should you buy at the current price?

The live buy range below is for members — two annuities at one fair price.

FAQ

What is the CRISIL share price target for 2030? Base case ≈ ₹6,870 (31× on 13% compounded growth), bear ≈ ₹4,240, bull ≈ ₹10,550. Arithmetic above.

What is CRISIL’s analytics business? Global Research & Risk Solutions — outsourced research, risk modelling and benchmarking for international banks and asset managers, delivered from India. It is the larger revenue segment.

Why does CRISIL trade richer than CARE Ratings? Brand premium in ratings, the global analytics annuity, and S&P parentage — quality layers CARE doesn’t carry, priced accordingly.

When are CRISIL’s next results? Track the exact date on our results calendar.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.